Dexgate
Vendor:
First CVE: Oct 19, 2023 · Active for 2 years
5
Total CVEs
More Total CVEs than 77% of tracked products
5.0
Avg CVEs / Year
Higher CVE frequency than 87% of tracked products
7.1
Avg CVSS
Higher Avg CVSS than 42% of tracked products
0.0%
KEV Rate
Bottom 1%
Trends Over Time
The number and severity of CVEs published that impact Dexgate over time
Volume of CVEsAvg CVSS Base Score
First CVE
Oct 19, 2023
2 years ago
Most Recent CVE
Oct 19, 2023
1,009 days ago
CVE Severity & Scoring
Dexgate5 CVEs
60%
40%
All CVEs352,294 CVEs
45%
40%
11%
MediumHigh
Attack Vector
Local0 (0.0%)
Network5 (100.0%)
Unknown0 (0.0%)
Physical0 (0.0%)
Adjacent Network0 (0.0%)
Attack Complexity
Low5 (100.0%)
High0 (0.0%)
Unknown0 (0.0%)
User Interaction
None1 (20.0%)
Unknown0 (0.0%)
Required4 (80.0%)
Privileges Required
Low0 (0.0%)
High0 (0.0%)
None5 (100.0%)
Unknown0 (0.0%)
Top CVEs
Signals from CVEs in this product scope (5 CVEs).
5 CVEs · Highest risk first
| CVE | Published | CVSS | Risk | KEV | Exploit |
|---|---|---|---|---|---|
CVE-2023-42435HIGH
The affected product is vulnerable to a cross-site request forgery vulnerability, which may allow an attacker to perform actions with the permissions of a victim user.
| Oct 19, 2023 | 8.8 | 26 | NO | NO |
CVE-2023-41089HIGH
The affected product is vulnerable to an improper authentication vulnerability, which may allow an attacker to impersonate a legitimate user as long as the device keeps th | Oct 19, 2023 | 8.8 | 24 | NO | NO |
CVE-2023-41088MEDIUM
The affected product is vulnerable to a cleartext transmission of sensitive information vulnerability, which may allow an attacker with access to the network, where clie | Oct 19, 2023 | 6.5 | 19 | NO | NO |
CVE-2023-40153MEDIUM
The affected product is vulnerable to a cross-site scripting vulnerability, which could allow an attacker to access the web application to introduce arbitrary Java Script by injec | Oct 19, 2023 | 6.1 | 19 | NO | NO |
CVE-2023-42666MEDIUM
The affected product is vulnerable to an exposure of sensitive information to an unauthorized actor vulnerability, which may allow an attacker to create malicious requ | Oct 19, 2023 | 5.3 | 17 | NO | NO |
Exploit Exposure
Signals from CVEs in this product scope (5 CVEs).
CISA KEV
0 CVEs
0.0% of CVEs· Bottom 1%
Metasploit
0 CVEs
0.0% of CVEs· Bottom 1%
Nuclei
0 CVEs
0.0% of CVEs· Bottom 1%
ExploitDB
0 CVEs
0.0% of CVEs· Bottom 1%
Social Chatter
Signals from CVEs in this product scope (5 CVEs).
Media Mentions
Signals from CVEs in this product scope (5 CVEs).
Top CNAs Publishing CVEs For Dexgate
Top CWEs
Versions
| Version | CVE Count | Avg CVSS | Avg EPSS | KEV | Exploits |
|---|---|---|---|---|---|
| 20130114 | 5 | 7.1 | 0.3% | 0 | 0 |